Compile Data Set for Download or QSAR
Report error Found 98 Enz. Inhib. hit(s) with all data for entry = 8897
TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426679(N-(3-(6-phenylquinazolin-8-yl)phenyl)acrylamide | ...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426678(N-(3-(2-amino-6-(2-chlorophenyl)quinazolin-8- yl)p...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426681(N-(3-(6-(pyridin-4-yl)quinazolin-8- yl)phenyl)acry...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426680(N-(3-(2-amino-6-phenylquinazolin-8- yl)phenyl)acry...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426675(1-(3-(5-amino-6-(4-phenoxyphenyl)quinazolin- 8-yl)...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426674(N-(3-(5-amino-6-(4-((4-(trifluoromethyl)pyridin- 2...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426677(1-(3-(5-amino-6-(2-fluoro-4-((4-(trifluoro- methyl...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426676(1-(3-(5-amino-6-(4-((4-(trifluoromethyl)pyridin- 2...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426673(N-(3-(5-amino-6-(2-fluoro-4-((4- (trifluoromethyl)...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426695(4-(5-(1-acryloylpyrrolidin-3-yl)pyrrolo[1,2- c]pyr...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426694(4-(5-(1-acryloylpyrrolidin-3-yl)pyrrolo[1,2- c]pyr...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426697(N-(3-(6-(3-fluorophenyl)quinazolin-8- yl)phenyl)ac...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426696(4-(8-(1-acryloylpyrrolidin-3-yl)quinazolin-6-yl)- ...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426691(4-(8-(3-acrylamidophenyl)quinazolin-6-yl)- 3-chlor...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426690(4-(8-(3-acrylamidophenyl)quinazolin-6-yl)- N-(3-(t...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426693(N-(3-(6-(6-phenoxypyridin-3-yl)quinazolin- 8-yl)ph...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426692(4-(8-(3-acrylamidophenyl)quinazolin-6-yl)- N-pheny...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426687(N-(3-(2-amino-6-(pyridin-3-yl)quinazolin-8- yl)phe...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426686(1-(3-(2-amino-6-(4-phenoxyphenyl)quinazolin- 8-yl)...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426689(1-(3-(6-(4-phenoxyphenyl)quinazolin-8- yl)pyrrolid...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426688(N-(3-(2-amino-6-(6-methylpyridin-3- yl)quinazolin-...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426683(4-(8-(3-acrylamidophenyl)quinazolin-6-yl)-N- (pyri...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426682(N-(3-(6-(pyridin-3-yl)quinazolin-8- yl)phenyl)acry...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426685(N-(3-(6-(4-phenoxyphenyl)quinazolin-8- yl)phenyl)a...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426684(N-(3-(6-(2-chlorophenyl)quinazolin-8- yl)phenyl)ac...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426711(4-(8-(3-acrylamidophenyl)quinazolin-6-yl)-3- chlor...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426710(N-(3-(6-(2-fluoro-4-(pyridin-2-yloxy)phenyl) quina...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426713(4-(8-(3-acrylamidophenyl)quinazolin-6-yl)- 3-chlor...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426712(N-(3-(6-(4-(pyridin-3-yloxy)phenyl) quinazolin-8-y...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426707(N-(3-(6-(2-fluoro-4-((3-fluoropyridin-2- yl)oxy)ph...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426706(N-(3-(2-amino-6-(5-chloropyridin-3- yl)quinazolin-...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426709(N-(3-(2-amino-6-(5-fluoropyridin-3- yl)quinazolin-...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426708(N-(3-(6-(4-((3-chloropyridin-2-yl)oxy)-2- fluoroph...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426703(N-(3-(2-amino-6-(2-cyanophenyl)quinazolin-8- yl)ph...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426702(N-(3-(6-(6-(3-fluorophenoxy)pyridin-3- yl)quinazol...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426705(N-(3-(6-(4-(pyrrolidine-1-carbonyl)phenyl) quinazo...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426704(N-(3-(6-(4-(pyridin-2-yloxy)phenyl)quinazolin- 8-y...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426699(N-(3-(6-(2-cyanophenyl)quinazolin-8- yl)phenyl)acr...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426698(N-(3-(6-phenyl-2-(phenylamino)quinazolin- 8-yl)phe...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426701(1-(3-(2-amino-6-(4-phenoxyphenyl)quinazolin- 8-yl)...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426700(N-(3-(2-(phenylamino)-6-(pyridin-3- yl)quinazolin-...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426727(N-(3-(2-amino-6-(2-methoxy-4-(pyridin-2- yloxy)phe...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426726(4-(8-(3-acrylamidophenyl)quinazolin-6-yl)- 2-chlor...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426729(N-(3-(6-(4-((4-(trifluoromethyl)pyridin-2- yl)oxy)...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426728(4-(8-(3-acrylamidophenyl)-5-aminoquinazolin- 6-yl)...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426723(N-(3-(2-amino-6-(2-fluoro-4-(pyridin-2- yloxy)phen...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426722(4-(8-(3-acrylamidophenyl)quinazolin-6-yl)-N- (4-cy...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426725(4-(5-(1-acryloylpyrrolidin-3-yl)pyrrolo[1,2- c]pyr...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426724(N-(3-(2-amino-6-(3-fluoro-4-(pyridin-2- yloxy)phen...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Neupharma

US Patent
LigandPNGBDBM426719(N-(3-(6-(3-fluoro-4-(pyridin-2-yloxy)phenyl) quina...)
Affinity DataIC50: 100nMAssay Description:To determine IC50 of a compound against a kinase, a series of concentrations of the compound were tested for the inhibition. IC50 was calculated by p...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2020
Entry Details
US Patent

Displayed 1 to 50 (of 98 total ) | Next | Last >>
Jump to: